YONG LI to Immunotherapy
This is a "connection" page, showing publications YONG LI has written about Immunotherapy.
Connection Strength
0.760
-
NK cells as powerful therapeutic tool in cancer immunotherapy. Cell Oncol (Dordr). 2024 Jun; 47(3):733-757.
Score: 0.140
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
Score: 0.126
-
Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021 11; 76:218-231.
Score: 0.116
-
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci. 2021 Apr; 64(4):534-547.
Score: 0.111
-
Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11).
Score: 0.109
-
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020 01 30; 19(1):19.
Score: 0.107
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
Score: 0.026
-
Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 08 23; 18(1):128.
Score: 0.026